Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer therapeutics in yeast.

Literature DB >> 12398890

Cancer therapeutics in yeast.

Abstract

The budding yeast Saccharomyces cerevisiae is a genetically tractable model system with which to establish the cellular target of a given agent and investigate mechanisms of drug action.

Entities: Disease Species

Mesh：

Substances：
Antineoplastic Agents

Year: 2002 PMID： 12398890 DOI： 10.1016/s1535-6108(02)00160-5

Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743

Keyword Cloud
Cited

15 in total

1. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.

Authors: Christine M Wright; Marié van der Merwe; Amanda H DeBrot; Mary-Ann Bjornsti
Journal: J Biol Chem Date: 2015-03-20 Impact factor: 5.157

2. Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.

Authors: Komaraiah Palle; Cyrus Vaziri
Journal: Cell Cycle Date: 2011-05-15 Impact factor: 4.534

3. Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.

Authors: Komaraiah Palle; Luca Pattarello; Marié van der Merwe; Carmen Losasso; Piero Benedetti; Mary-Ann Bjornsti
Journal: J Biol Chem Date: 2008-08-08 Impact factor: 5.157

4. Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast.

Authors: Álvaro Cuesta-Marbán; Javier Botet; Ola Czyz; Luis M Cacharro; Consuelo Gajate; Valentín Hornillos; Javier Delgado; Hui Zhang; Francisco Amat-Guerri; A Ulises Acuña; Christopher R McMaster; José Luis Revuelta; Vanina Zaremberg; Faustino Mollinedo
Journal: J Biol Chem Date: 2013-01-18 Impact factor: 5.157

Cancer therapeutics in yeast.

1. DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.

2. Rad18 E3 ubiquitin ligase activity mediates Fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 inhibition.

3. Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.

4. Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast.

5. Chemotypic variation of essential oils in the medicinal plant, Anemopsis californica.

6. TOR signaling is a determinant of cell survival in response to DNA damage.

Review 7. Application of anhydrobiosis and dehydration of yeasts for non-conventional biotechnological goals.

8. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.

9. Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.

10. Warburg effect and translocation-induced genomic instability: two yeast models for cancer cells.